Evidence map›Paper›PMID 23372797›Full record

ArticlePloS one2013

Identification of GPCR-interacting cytosolic proteins using HDL particles and mass spectrometry-based proteomic approach.

Ka Young Chung, Peter W Day, Gisselle Vélez-Ruiz, Roger K Sunahara, Brian K Kobilka

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Nanodiscs and Mass Spectrometry: Making Membranes Fly.International journal of mass spectrometry · 2020
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Nanobodies to Study G Protein-Coupled Receptor Structure and Function.Annual review of pharmacology and toxicology · 2017
    Review
  11. Article
  12. Article
  13. Novel Structural Approaches to Study GPCR Regulation.International journal of molecular sciences · 2016
    Review
  14. Review
  15. Review
  16. Article
  17. The structural basis of G-protein-coupled receptor signaling (Nobel Lecture).Angewandte Chemie (International ed. in English) · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Ka Young ChungDepartment of Molecular and Cellular Physiology, Stanford University, Medical School, Beckman Center, Stanford, California, United States of America. kychung2@skku.edu
Peter W Day
Gisselle Vélez-Ruiz
Roger K Sunahara
Brian K Kobilka
Michigan United · USStanford University · USSungkyunkwan University · KR

Funding

CELLULAR AND MOLECULAR BIOLOGY AT MICHIGANT32GM007315 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PUTHENVEEDU, MANOJKUMAR A · 1985 to 2021
$12.8M
Structure and dynamics of G protein coupled receptor-G protein complexesR01GM083118 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOBILKA, BRIAN K, SKINIOTIS, GEORGIOS · 2008 to 2023
$8.3M
Beta Adrenoceptor Signaling Complexes in Innervated Cardiac MyocytesR01HL071078 · NHLBI · STANFORD UNIVERSITY · PI KOBILKA, BRIAN K · 2002 to 2012
$3.5M
LTQ Orbitrap XL ETD Mass SpectrometerS10RR027425 · NCRR · STANFORD UNIVERSITY · PI WANDLESS, THOMAS JAMES · 2010 to 2010
$500k
NCRR NIH HHS S10 RR027425NCRR NIH HHS S10RR027425NHLBI NIH HHS R01 HL071078NIGMS NIH HHS GM083118NIGMS NIH HHS R01 GM083118NIGMS NIH HHS T32 GM007315
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) have critical roles in various physiological and pathophysiological processes, and more than 40% of marketed drugs target GPCRs. Although the canonical downstream target of an agonist-activated GPCR is a G protein heterotrimer; there is a growing body of evidence suggesting that other signaling molecules interact, directly or indirectly, with GPCRs. However, due to the low abundance in the intact cell system and poor solubility of GPCRs, identification of these GPCR-interacting molecules remains challenging. Here, we establish a strategy to overcome these difficulties by using high-density lipoprotein (HDL) particles. We used the β(2)-adrenergic receptor (β(2)AR), a GPCR involved in regulating cardiovascular physiology, as a model system. We reconstituted purified β(2)AR in HDL particles, to mimic the plasma membrane environment, and used the reconstituted receptor as bait to pull-down binding partners from rat heart cytosol. A total of 293 proteins were identified in the full agonist-activated β(2)AR pull-down, 242 proteins in the inverse agonist-activated β(2)AR pull-down, and 210 proteins were commonly identified in both pull-downs. A small subset of the β(2)AR-interacting proteins isolated was confirmed by Western blot; three known β(2)AR-interacting proteins (Gsα, NHERF-2, and Grb2) and 3 newly identified known β(2)AR-interacting proteins (AMPKα, acetyl-CoA carboxylase, and UBC-13). Profiling of the identified proteins showed a clear bias toward intracellular signal transduction pathways, which is consistent with the role of β(2)AR as a cell signaling molecule. This study suggests that HDL particle-reconstituted GPCRs can provide an effective platform method for the identification of GPCR binding partners coupled with a mass spectrometry-based proteomic analysis.

Indexed as

Mass SpectrometryProteomicsAnimalsCarrier ProteinsCell LineComputational BiologyCytosolImmunoprecipitationLipoproteins, HDLProtein BindingProtein Interaction MappingRatsReceptors, Adrenergic, beta-2Receptors, G-Protein-CoupledReproducibility of ResultsCarrier ProteinsLipoproteins, HDLReceptors, Adrenergic, beta-2Receptors, G-Protein-Coupled

Identifiers

PMID23372797
PMCPMC3556083
OpenAlexW2099087615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.